Fermion and Simcere Enter into an Exclusive License and Collaboration Agreement for China's First SSTR4 Agonist Targeting Pain
Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4.
Pharmabiz17h
Fermion and Simcere Pharma ink partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4
Fermion and Simcere Pharma ink partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4: Guangzhou, China Monday, January 20, 2025, 11:00 Hrs [IST] ...
https//businessnewswales.com9h
Final Weeks to Submit Entries for the Wales Food and Drink Awards 2025
Food and drink producers across Wales, take note: the deadline to enter the prestigious Wales Food and Drink Awards 2025 is ...